AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02848235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care + EMMA
Description: Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
Study NCT02202590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECM Capsule
Description: Imaging of the esophagus using the SECM capsule and system
Study NCT01447355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study NCT01580527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total parenteral nutrition
Description: Total parenteral nutrition in postoperative of pancreaticoduodenectomy
Study NCT01580527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Early enteral nutrition in postoperative of pancreaticoduodenectomy
Study NCT01056211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment
Description: Starlux 300 Lux 1540nm Fractional laser hand piece
Study NCT01056211 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: treatment without laser
Description: Starlux 300 Lux 1540nm Fractional laser hand piece
Study NCT03293719 — intervention group
Intervention type: DEVICE
Intervention: BPK-S Integration UC
Description: Primary Knee Endoprosthesis
Study NCT03042442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of care biomarkers
Description: Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
Study NCT03042442 — intervention group
Intervention type: OTHER
Intervention: Clinical, venous blood samples, pancreatic tissue
Description: Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
Study NCT03042442 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Participants will be assessed (by telephone) over a period of 2 years
Study NCT02034435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Salt diet plus Placebo tablet
Study NCT02105766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Immunosuppressant
Study NCT02105766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Immunosuppressant
Study NCT02034435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Sodium diet plus Salt tablet
Study NCT02034435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epleronone
Description: 50mg daily
Study NCT02034435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg daily
Study NCT01539941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication integration protocol
Description: MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
Study NCT03848312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 45 computerized sessions.
Study NCT03848312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Stimulation
Description: Participants will be completing a total of 45 computerized cognitive stimulation sessions.
Study NCT02105766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Immunosuppressant and myelosuppressant
Study NCT02105766 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: mobilize peripheral blood stem cells for apheresis collection
Study NCT04429243 — intervention group
Intervention type: DEVICE
Intervention: GORE® VIABAHN® Stent Graft
Description: On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
Study NCT03186898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy (Radiation Therapy)
Description: Undergo proton therapy
Study NCT03186898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Therapy (Radiation Therapy)
Description: Undergo photon therapy
Study NCT04293354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Plane Block
Description: Serratus Plane Block was performed
Study NCT04293354 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No block was performed
Study NCT01195220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
Study NCT01195220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI/HIV-T
Description: This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
Study NCT01195220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI/HIV-Plus
Description: This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
Study NCT01849458 — intervention group
Intervention type: DEVICE
Intervention: BioFiber
Description: Subjects implanted with BioFiber or BioFiber-CM Scaffold
Study NCT00858416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kineticure System followed by sham
Description: 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
Study NCT00858416 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham followed by Kineticure System
Description: sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
Study NCT04989569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
Study NCT00942734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: One tablet (150 mg) by mouth every day of each 28 day study cycle.
Study NCT00942734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 1 tablet (5 mg) by mouth every day of each 28 day study cycle.
Study NCT02969707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro TMS system (MagVenture, Denmark)
Description: The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
Study NCT02969707 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro TMS system (MagVenture, Denmark)
Description: The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
Study NCT02969707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
Study NCT02969707 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hypnosis
Description: Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
Study NCT04329975 — intervention group
Intervention type: DRUG
Intervention: Desmopressin
Description: Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
Study NCT02438527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chart for CPR guidance
Study NCT01082731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
Study NCT01082731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine- Artesunate
Description: Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
Study NCT03522753 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Metal skin staples
Description: Routine closure methods/material for surgical wounds
Study NCT03522753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal skin staples
Description: Routine closure methods/material for surgical wounds
Study NCT03522753 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nylon sutures
Description: Routine closure methods/material for surgical wounds
Study NCT03522753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon sutures
Description: Routine closure methods/material for surgical wounds
Study NCT02622750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: triple-branched stent graft
Description: place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
Study NCT02622750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: four-branched Dacron graft
Description: The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft.
Study NCT02234934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentiviral G1XCGD Gene Therapy
Description: The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve > 0.3 integrated copies per cell.
Study NCT03233776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
Study NCT04223648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
Description: Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy.
Study NCT03486431 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
Study NCT01124617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
Study NCT01124617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
Study NCT01183884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Description: 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2.
Study NCT00660387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa carbidopa intestinal gel (LCIG)
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Study NCT00660387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Gel
Study NCT00660387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
Study NCT00660387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO) oral capsules
Study NCT00660387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT00660387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT00660387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT00660387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT00660387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study NCT00660387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: J-tube
Description: jejunal tube
Study NCT01457092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)
Description: Placement of self-expandable metal stents
Study NCT04009876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Study NCT04009876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection of the tumour
Study NCT04009876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch-and-wait
Description: No surgery approach
Study NCT04009876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Study NCT04009876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Study NCT02213887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg PO QAM
Study NCT02213887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0 mg PO QAM
Study NCT04219527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-target injection
Description: Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)
Study NCT00856349 — intervention group
Intervention type: BEHAVIORAL
Intervention: Therapy Programming Report (TPR)
Description: Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
Study NCT02914457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological Study
Description: Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
Study NCT03419962 — intervention group
Intervention type: DRUG
Intervention: MaxSpiolto® Respimat® 160 Characters...
Description: as per the approved SmPC
Study NCT01485718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucomannan
Description: Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
Study NCT01485718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
Study NCT02754492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure